Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:54 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib
NCT02398825 · Gruppo Italiano Malattie EMatologiche dell'Adulto · PHASE2 · terminated · last registry update 2025-01-17 · Chronic myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “low enrollment rate” | Open Targets' class: insufficient enrollment | Registry record, Gruppo Italiano Malattie EMatologiche dell'Adulto |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ABL1 in chronic myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-01-15Results posted on the registry: M.D. Anderson Cancer Center, Dasatinib (NCT00254423)
- 2026-01-09Results posted on the registry: M.D. Anderson Cancer Center, Asciminib (NCT04216563)
- 2025-12-18Results posted on the registry: SWOG Cancer Research Network, Bosutinib + Dasatinib (NCT03654768)
- 2025-06-03Also stopped (terminated): M.D. Anderson Cancer Center, Dasatinib + Imatinib Mesylate (NCT01751425)
- 2025-03-27Results posted on the registry: Novartis Pharmaceuticals, ABL001 40mg BID + ABL001 80mg QD (NCT04948333)
- 2025-03-10Results posted on the registry: Novartis Pharmaceuticals, Imatinib + Nilotinib (NCT04971226)
- 2025-02-14Results posted on the registry: Novartis Pharmaceuticals, Asciminib add-on + Imatinib (NCT03578367)
- 2024-07-12Results posted on the registry: Novartis Pharmaceuticals, ABL001 (NCT04666259)
- 2024-05-21Phase 3 first posted: Ascentage Pharma Group Inc., olverembatinib + Bosutinib (NCT06423911)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision